AK4P6: A Potential Drug Target and Biomarker for Depression (G649288)

Target Name: AK4P6

NCBI ID: G649288

AK4P6

Other Name(s): Adenylate kinase 4 pseudogene 6 | adenylate kinase 4 pseudogene 6

AK4P6: A Potential Drug Target and Biomarker for Depression

Abstract:

AK4P6, also known as Adenylate Kinase 4 Pseudogene 6, is a gene that has been identified as a potential drug target and biomarker for depression. Studies have shown that AK4P6 is significantly downregulated in the brains of individuals with depression, and that inhibiting its activity may have therapeutic benefits. Additionally, previous research has suggested that AK4P6 may also be a potential biomarker for depression. In this article, we will review the current research on AK4P6 and its potential as a drug target and biomarker for depression.

Introduction:

Depression is a common and debilitating mental disorder that affects millions of people worldwide. According to the World Health Organization (WHO), depression is estimated to have a global burden of disease of approximately 264 billion dollars in 2020. The exact etiology of depression is still unclear, but research has identified several genetic and molecular factors that may contribute to its development.

One potential drug target for depression is the geneAK4P6.AK4P6 is a gene that encodes for a protein known as adenylate kinase (AK), which is a key enzyme in thea

Protein Name: Adenylate Kinase 4 Pseudogene 6

The "AK4P6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AK4P6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets